Axi-cel, an Anti-CD19 Chimeric Antigen Receptor (CAR) T cell Therapy in Adult Patients (Pts) With Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) in the ZUMA-3 Trial: Preliminary Results of Novel Safety Interventions

Outcomes in adult R/R ALL are poor. Promising results were observed with axi-cel (formerly KTE-C19) in B cell malignancies. Severe cytokine release syndrome (CRS) and neurologic events (NE) have been observed with anti-CD19 CAR T cell therapy in R/R ALL.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Bijal Shah, Wendy Stock, William Wierda, Max Topp, Marie Jos é Kersten, Roch Houot, Nicolas Boissel, Houston Holmes, Gary Schiller, Armen Mardiros, John Rossi, Yizhou Jiang, Tong Shen, Jeff Aycock, Shanna Stout, Jeff Wiezorek, Rajul Jain Source Type: research